ArticleMikrochimica acta2026
Development and human samples validation of a plasma pTau‑217 electrochemical sensor for Alzheimer's detection in Vietnamese patients.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A multi-walled carbon nanotube - poly (allylamine hydrochloride acid)/platinum nanoparticle (MWCNT-PAH/PtNP) biosensor for phosphorylated Tau-217 (pTau-217) detection and validated using Alzheimer’s disease (AD) plasma samples is described. Morphological characterization confirmed successful deposition of MWCNT-PAH/PtNP, which enhanced the sensor’s surface height range (bare sensor |∆| = 2.2 μm vs. modified sensor |∆| = 5.7 μm) and electrochemical properties. The sensor achieved a detection limit of 9.85 pg/mL by cyclic voltammetry (CV) and 3.83 pg/mL by chronoamperometry (CA), and could detect pTau-217 in the presence of interfering molecules and in complex protein-rich matrices such as fetal bovine serum (FBS). When validated on clinical samples, the sensor could distinguish AD from cognitive normal (CN ) samples more effectively than ELISA (AUCCV: 90.75%; AUCCA: 87.13%; AUCELISA: 52.52%). Subgroup analysis revealed that sensor output primarily reflected disease status, with minimal confounding effects from demographic or social factors. However, a key limitation is that current intensity cannot be directly converted into plasma pTau-217 concentration, restricting the sensor to qualitative AD screening rather than precise quantification. Taken together, this biosensor holds great potential as a cost-effective tool for distinguishing AD and CN plasma samples, with promising prospects for on-site application.
Indexed as
Identifiers
41711970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.